Navigation Links
Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt
Date:5/22/2013

ere Langzeitstudie beider Dosen von PROLASTIN-C. Die unter dem Namen SPARTA laufende Studie wird die erste und einzige klinische Studie für die Auswertung der Wirksamkeit von PROLASTIN-C mit der Standarddosis von 60 mg/kg und der Dosis von 120 mg/kg gegenüber Placebos sein. Die SPARTA-Studie wird CT Lungendensiometrie zur Messung des Grades der Konservierung von Lungengewebe über einen bestimmten Zeitraum hinweg verwenden. Bei der SPARTA-Studie handelt es sich um eine multizentrische Studie, deren Beginn in der zweiten Hälfte 2013 geplant ist.

Über Grifols

Grifols ist ein globales Unternehmen der Gesundheitsbranche mit einer 70-jährigen Tradition bei der Verbesserung der Lebensqualität von Menschen mithilfe lebensrettender Arzneimittel aus Plasma, pharmazeutischer Produkte für Krankenhäuser und von Diagnosetechnik für den klinischen Einsatz.

Als weltweit drittgrößter Hersteller von Arzneimitteln aus Plasma ist Grifols in über 100 Ländern vertreten und mit 150 Plasma-Spendenzentren in den USA Weltmarktführer bei der Plasmasammlung. Grifols ist dem Ziel verpflichtet, den Zugang zu lebensrettenden Plasmamedikamenten für Patienten durch wesentliche Produktionsausweitungen und durch die Entwicklung neuer therapeutischer Anwendungen von Plasmaproteinen zu verbessern. Der Hauptsitz des Unternehmens befindet sich in Barcelona, Spanien, und es beschäftigt weltweit mehr als 12.000 Mitarbeiter.

Im Jahr 2012 überstieg der Umsatz von Grifols 2.620 Millionen Euro. Die A-Aktien des Unternehmens werden an der spanischen Börse gehandelt und wurden in den Ibex-35 (MCE: GRF) aufgenommen. Die nicht stimmberechtigten B-Aktien sind am Mercado Continuo (MCE: GRF.P) zugelassen und werden an der US -amerikanischen NA
'/>"/>

SOURCE Grifols
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. RNL BIO Co. Ltd. stellt IND-Antrag, um klinische Phase-II-Studie des RNL-JointStem gegen Arthrose in den Vereinigten Staaten einzuleiten
2. Acutus Medical, Inc. erprobt erstmals seinen Echtzeit-3D-Bildgebungskatheter von CT/MRI-Qualität in einer klinischen Studie am Menschen
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Eine in European Radiology veröffentlichte Studie untermauert den Nutzen von Hologics Brust-Tomosynthese beim Screening bei Verfahren mit Zweitbefundung
6. Neuartige Krebsimmuntherapie für den Beginn klinischer Studien bereit
7. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
8. Studies Published in Pain Medicine Demonstrate Effectiveness of Minimally-Invasive Cooled Radiofrequency Treatment for Low Back Pain
9. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
10. Managing Bioequivalence Studies to Optimize Cost, Quality, and Outsourcing of Generics Manufacturing
11. Studies Show Pharma has a Strong Opportunity to Market to New Decision Makers via Digital Channels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Today, ... a new extension to its PageCenterX ® ... software is designed to provide downtime reporting capabilities ... outages. LRS is releasing the product for general ... environment, EMR applications experience outages for a variety ...
(Date:7/31/2014)... CITY, Calif. , July 31, 2014  Genomic Health, ... company will host a conference call and webcast on Thursday, ... second quarter 2014 financial results.  The call and webcast will ... market close. Conference Call Details To access the ... Time via phone, please dial (877) 303-7208 from ...
(Date:7/31/2014)... 31, 2014 Nutrastar International Inc. (OTCQB: NUIN; ... of premium branded consumer products, including commercially cultivated Cordyceps ... today announced the signing of its first distributor for ... to Hubei Province ... China . The contract with ...
Breaking Medicine Technology:LRS Announces Downtime Reporting Solution for Healthcare 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... March 5 A study published by Deborah ... the Journal of Drugs in Dermatology ... resurfacing technologies, specifically, the SmartXide DOT(TM) laser. DOT utilizes ... for rapid healing, less downtime and profound results. Dr. ...
... Complications Reported With Coronary DeviceDOYLESTOWN, Pa., March 4 ... in February by completing the enrollment of 30 ... clinical trial for the vProtect(TM) Luminal Shield, conducted ... Shield successfully crossed all target lesions and was ...
Cached Medicine Technology:New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation 2Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield 2
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 ... H2 2014, provides an overview of the Brain ... information on the therapeutic development for Brain Cancer, ... assessment by drug target, mechanism of action (MoA), ... with latest updates, and featured news and press ...
(Date:7/31/2014)... July 31, 2014 Much of the liver,s metabolic ... body clock and UC Irvine researchers have now ... The study, published online today in Cell , ... metabolism and points the way to more focused drug ... obesity and diabetes. , Paolo Sassone-Corsi, UCI,s Donald Bren ...
(Date:7/31/2014)... The virus that causes cold sores -- herpes simplex type ... according to a new study. Researchers in Australia ... infected with the virus. This explains why some people with ... them only occasionally. The authors said the findings could lead ... when the disease was dormant, it was a truce. It ...
(Date:7/31/2014)... 31, 2014 i2i Systems announced today ... Inc. (SAS) to provide a robust patient referral ... SAS is one of the largest independent software companies ... than 40,000 patients are seen annually in its on-site ... delivering primary care, providers at the SAS HCC refer ...
(Date:7/31/2014)... Over the past five years, the ... the estimated 151 million individuals that have required some ... of Ophthalmology (AAO). According to a Consumer Reports National ... vision correction surgery, a large share of consumers have ... medical procedure was to eliminate the use of glasses ...
Breaking Medicine News(10 mins):Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 4Health News:Strict genomic partitioning by biological clock separates key metabolic functions 2Health News:Cold Sore Virus Active Without Symptoms, Study Finds 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 3Health News:Eye Surgery Clinics in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Eye Surgery Clinics in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... , , , ... e-Zassi.com(TM), an online decision support software system, integrated business ... has partnered with Medical Development Group (MDG), a medical device ... agreement, MDG will provide access to the e-Zassi platform to ...
... Aug. 12 Hank Oprinski, the CEO at Cap ... tour to inform corporations, chambers of commerce, golfing communities, economic clubs, universities ... , What did all the following businessmen have ... Tiger Woods) , Merv Griffin (TV Producer) , Tom Witter (Dean/Witter/Reynolds) , ...
... , , , ... today that its CardioVasc Advantage(TM) Vascular Reconstruction Device has been ... , "The technology of the Advantage VRD ... noted company Chairman, Eric P. Milledge. "The technical platform behind ...
... , , , ... create expensive home health care costs. Poorly designed mobility aids or ... issue only part of the need is addressed which creates mobility ... alleviated if mobility issues were detected and properly addressed. , ...
... , , LONDON, Aug. ... optimal and efficient way and, at the same time, adhere ... pharmacovigilance tools and technologies. , , (Logo: ... Frost & Sullivan ( http://www.healthcareIT.frost.com ), World Pharmacovigilance Markets ...
... ... A GPS navigation device allows you to most accurately ... above the Earth’s surface - instantly. This multi-perspective triangulation clearly leads ... performance measurement system incorporates a number of key vital signs from ...
Cached Medicine News:Health News:Medical Development Group Partners with e-Zassi.com(TM) to Provide Members Access to Exciting New Software Tool 2Health News:Medical Development Group Partners with e-Zassi.com(TM) to Provide Members Access to Exciting New Software Tool 3Health News:September is Prostate Cancer Awareness Month 2Health News:Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 2Health News:Expensive Health Care: Undetected, Unmet Mobility Needs Creating Boomer & Senior Health Care Costs 2Health News:Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 2Health News:Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 3Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 2Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 3
This suture adjuster facilitates post operative suture adjustment of running sutures while decreasing the possibility of suture damage or breakage....
11.5 mm curved hook. Flat serrated handle with polished finish. Overall length: 5.9 inches....
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
0.3 mm hook angled 45 degrees, 9 mm from tip to bend. Flat smooth handle with polished finish. Overall length: 4.6 inches....
Medicine Products: